Potential therapeutic application of EP4 agonists
Agonist | Route | Dose | Species | Experimental Model | Indication | Reference |
---|---|---|---|---|---|---|
3,7-Dithia PGE1 and its isopropyl ester | Topical | 0.01–0.1% | Monkey | “Glaucomatous” monkey intraocular pressure | Glaucoma | Woodward et al., 2009 |
4819-CD | Subcutaneous | 0.3 mg/kg | Mouse | Ischemia-reperfusion injury | Myocardial infarction | Xiao et al., 2004 |
AEI-734 | Colitis | Kabashima et al., 2002 | ||||
AGN 205203 and its methyl ester | Subcutaneous | 3 mg/kg | Mouse | Dextran sodium sulfate colitis | Colitis | Jiang et al., 2007 |
CP-734432 | Subcutaneous | 0.3–3 mg/kg | Rat | Ovariectomized rats | Osteoporosis | Ke et al., 2006 |
ONO-4819 | Subcutaneous | 10, 30 μg/kg | Rat | Femoral drill-hole injury | Bone fracture healing, osteoporosis | Tanaka et al., 2004 |
ONO-4819 | Subcutaneous | 3, 30 μg/kg | Rat | Mechanical loading, to tibia | Bone fracture, osteoporosis | Hagino et al., 2005 |
ONO-4819 | Intravenous | 100 ng/kg | Rat | Ovariectomized rat | Osteoporosis | Yoshida et al., 2002 |
ONO-AE1-329 | Intracolonic | 25, 100 μg/kg | Rat | Dextran sodium sulfate colitis | Colitis | Nitta et al., 2002 |
ONO-AE1-329 | Intravenous | 1–10 μg/kg | Rat | Indomethacin-induced lesions | NSAID-induced gastrointestinal lesions | Kunikata et al., 2002 |
ONO-AE1-329 | Intraperitoneal | 0.1 mg/kg | Rat | Indomethacin-induced lesions | NSAID-induced gastrointestinal lesions | Hatazawa et al., 2006 |
ONO-AE1-329 | Subcutaneous | 0.1–1000 ng/g | Rat | Neonatal ductus arteriosus dilatation | Premature birth | Momma et al., 2005 |
ONO-AE1-329 | Local gelatin plug | 1 mg/ml | Guinea pig | Auditory brain stem response | Sensorineural hearing loss | Hori et al., 2009 |
ONO-AE1-329 | Subcutaneous | 0.05, 0.5 mg/kg 55 μg daily infusion per animal | Mouse | N2 receptor knockout mice | Nephrogenic diabetes insipidus | Li et al., 2009 |
ONO-AE1-329 | Subcutaneous | 100 μg/kg | Mouse | Anti-glomerular basement membrane antibody nephritis | Glomerulonephritis | Nagamatsu et al., 2006 |
ONO-AE1-329 | Intravenous | 1–10 μg/kg | Rat | Endotoxin | Septicemia | Sakamoto et al., 2004 |
PF-04475270 | Topical | 0.002–0.1 mg/ml | Dog | Normal dog intraocular pressure | Glaucoma | Prasanna et al., 2009 |